ALG14

Chr 1AR

ALG14 UDP-N-acetylglucosaminyltransferase subunit

Also known as: CMS15, IDDEBF, MEPCA

This gene is a member of the glycosyltransferase 1 family. The encoded protein and ALG13 are thought to be subunits of UDP-GlcNAc transferase, which catalyzes the first two committed steps in endoplasmic reticulum N-linked glycosylation. Mutations in this gene have been linked to congenital myasthenic syndrome (CMSWTA). Alternatively spliced transcript variants have been identified. [provided by RefSeq, Mar 2015]

Primary Disease Associations & Inheritance

?Myasthenic syndrome, congenital, 15, without tubular aggregatesMIM #616227
AR
Intellectual developmental disorder with epilepsy, behavioral abnormalities, and coarse faciesMIM #619031
AR
Myopathy, epilepsy, and progressive cerebral atrophyMIM #619036
AR
0
Active trials
9
Pathogenic / LP
180
ClinVar variants
6
Pubs (1 yr)
0.3
Missense Z
1.20
LOEUF
Clinical SummaryALG14
🧬
Gene-Disease Validity (ClinGen)
congenital disorder of glycosylation · ARLimited

Limited evidence — not for standalone diagnostic reporting

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
9 Pathogenic / Likely Pathogenic· 93 VUS of 180 total submissions
📖
GeneReview available — ALG14
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
1.20LOEUF
pLI 0.001
Z-score 1.15
OE 0.61 (0.331.20)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint
0.27Z-score
OE missense 0.93 (0.801.09)
118 obs / 126.4 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.61 (0.331.20)
00.351.4
Missense OE0.93 (0.801.09)
00.61.4
Synonymous OE0.90
01.21.6
LoF obs/exp: 6 / 9.9Missense obs/exp: 118 / 126.4Syn Z: 0.55
DNGOF
DN
0.7035th %ile
GOF
0.6345th %ile
LOF
0.2970th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

180 submitted variants in ClinVar

Classification Summary

Pathogenic8
Likely Pathogenic1
VUS93
Likely Benign64
Benign7
Conflicting7
8
Pathogenic
1
Likely Pathogenic
93
VUS
64
Likely Benign
7
Benign
7
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
1
7
0
8
Likely Pathogenic
0
0
1
0
1
VUS
5
78
10
0
93
Likely Benign
0
8
25
31
64
Benign
0
1
5
1
7
Conflicting
7
Total5884832180

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

ALG14 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Landmark / reviewRecent case evidence